Fluocinolone acetonide (Iluvien) extended-release intravitreal implant for diabetic macular edema. (April 2014)

• Record Type: Journal Article
• Authors: Carle, Michelle V; Chu, Thomas G; Boyer, David S
• Is Part Of: Expert review of ophthalmology. Volume 9:Number 2(2014)
• Page Start: 81
• Page End: 88
• Publication Date: 2014-04
• Subjects: Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1586/17469899.2014.902310
• Languages: English
• ISSNs: 1746-9899

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Fluocinolone acetonide (FAc) is a corticosteroid used in the FAc implant, a novel drug-delivery device currently approved in Europe but not yet approved in the USA. The drug delivery system for FAc implant allows a sustained delivery in a more posterior location in the eye and can be delivered in an outpatient setting. It has been shown to reduce diabetic macular edema via multiple mechanisms including the VEGF pathway. This allows for a more complete resolution in foveal thickness and leakage on fluorescein angiography, which increases best corrected visual acuity. Side effects, such as cataract and increased intraocular pressure, are common for ocular steroids.</p> </abstract>